文献速递类风湿关节炎

生物制剂治疗类风湿关节炎的缓解标准评估

Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease-Modifying Antirheumatic Drugs.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-06-05

研究纳入306例开始或更换bDMARDs的RA患者,分析6个月时EULAR(基于ESR或CRP)、SDAI50和CDAI50缓解标准的一致性。TNF抑制剂或CTLA4-Ig治疗者各标准一致性良好(κ>0.6),但IL-6i治疗者EULAR(ESR)与SDAI50/CDAI50一致性低(κ=0.43/0.37)。结论认为EULAR标准在IL-6i治疗中因APR改善对DAS28贡献大而高估缓解。

要点

  • IL-6i治疗者EULAR(ESR)与SDAI50/CDAI50一致性低(κ=0.43/0.37)。
  • IL-6i治疗下APR改善占DAS28(ESR)总改善的56.0%。
  • CDAI50与EULAR不一致时均为EULAR-only缓解者,且无HAQ改善。

核心结论

  • EULAR缓解标准在IL-6i治疗中高估缓解,因APR改善对DAS28改善贡献大。

研究设计与样本

  • 纳入306例开始或更换bDMARDs的RA患者,分析6个月治疗反应,用Kappa统计评估不同缓解标准间一致性。

主要发现

  • TNF抑制剂或CTLA4-Ig治疗者各缓解标准间一致性良好,κ>0.6。
  • IL-6i治疗者EULAR(ESR)与SDAI50一致性κ=0.43,与CDAI50一致性κ=0.37。
  • IL-6i治疗下APR改善占DAS28(ESR)总改善的56.0%。
  • CDAI50与EULAR不一致时均为EULAR-only缓解者,且无HAQ改善。

关键数值与推荐

  • EULAR缓解基于ESR或CRP水平、SDAI50和CDAI50为评估的缓解标准。
  • 一致性判断采用Kappa统计,κ>0.6为良好一致性。

临床怎么用

  • IL-6i治疗RA评估疗效时,应谨慎解读基于ESR的EULAR缓解标准,优先采用SDAI50或CDAI50等不依赖APR的复合指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Biologic disease-modifying antirheumatic drugs (bDMARDs) used for rheumatoid arthritis (RA) treatment have several mechanisms of action. Interleukin-6 inhibitors (IL-6i) block the production of acute-phase reactants (APRs), which are some of the composite measures of disease activity. We undertook this study to examine the agreement between the European League Against Rheumatism (EULAR) response based on the erythrocyte sedimentation rate (ESR) or C-reactive protein level, the Simplified Disease Activity Index 50% response measure (SDAI50), and the Clinical Disease Activity Index 50% response measure (CDAI50) in patients treated with IL-6i and other bDMARDs. METHODS: We enrolled 306 patients with RA who started or switched bDMARDs. Treatment response at 6 months was analyzed. Kappa statistics were used to evaluate the agreement between different response measures. The contribution of APRs to improvement in disease activity scores was examined. The change of Health Assessment Questionnaire (HAQ) score was analyzed in IL-6i-treated patients. RESULTS: Good agreement was achieved between response measures, with κ >0.6 in patients treated with tumor necrosis factor inhibitors or cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin fusion protein. In IL-6i-treated patients, the agreement was low between the EULAR response (ESR) and the SDAI50 or the CDAI50 (κ = 0.43 and 0.37, respectively). Under IL-6i treatment, APR improvement accounted for 56.0% of total improvement of the Disease Activity Score in 28 joints (DAS28) using the ESR. When discordance was found between the CDAI50 and EULAR response in IL-6i-treated patients, all patients were classified as EULAR-only responders; there was no HAQ improvement in EULAR-only responders. CONCLUSION: EULAR response criteria overestimate the response under IL-6i treatment because the APR improvement largely contributes to the DAS28 improvement.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Inoue M, Kanda H, Tateishi S, et al. Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease-Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken). 2020. PMID: 31058442. doi:10.1002/acr.23914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。